Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology
Immunai, an AI-driven biotech company focused on mapping the human immune system, has partnered with Teva Pharmaceuticals in a multi-year collaboration aimed at improving clinical trial outcomes for oncology and immunology therapies.
The collaboration will use Immunai’s proprietary immune cell atlas, AMICA, and its AI-powered Immunodynamics Engine (IDE) to enhance clinical decision-making. This tech will help deepen the understanding of drug mechanisms of action, optimize dose selection, and analyze biomarkers to improve trial success rates and patient outcomes.
Briefly, the AMICA platform—Annotated Multi-Omic Immune Cell Atlas—is reportedly the world’s largest single-cell immune knowledge base. It includes tens of millions of cells mapped across hundreds of disease settings and integrates over 5,000 studies, including more than 350 single-cell investigations. AMICA encompasses data on over 80 immune cell types, spanning 500 diseases, with insights derived from more than 100,000 patient samples. This resource powers the IDE, which combines functional genomics and advanced AI to uncover therapeutic biomarkers, validate hypotheses, and identify patient subgroups for clinical trials.
Noam Solomon, Ph.D., CEO of Immunai:
“Bringing a drug to market is inherently challenging, time-consuming, and costly. Through our partnership with Teva, we are eager to utilize our AI-based engine to streamline this process and help deliver new therapies to patients.”
Eran Harary, Senior Vice President and Global Head of Specialty R&D at Teva Pharmaceuticals:
“Partnering with Immunai enables us to leverage AI solutions that will enhance our research and development strategy. This collaboration will provide important insights into patient responses and treatment mechanisms, allowing us to optimize our clinical trials and improve outcomes for patients.”
Looking ahead, the partnership could expand to include broader areas of Teva’s research and development portfolio. Both companies emphasize their commitment to using innovative technology to bring faster, more effective solutions to patients.
Topic: Biotech Ventures
